Continuous cisplatin infusion in combination with vincristine and high-dose methotrexate for advanced osteogenic sarcoma.
Fifteen patients with metastatic osteogenic sarcoma (OS) were treated with a combination of Vincristine (1.4 mg/m2), high-dose Methotrexate (8 g/m2), and Cisplatin (120 mg/m2 as a 72-h continuous infusion). The overall response rate was 66% [5 complete response (CR) and 5 partial response (PR)]. Four of the six patients not previously treated had a CR. Toxicity from this regimen was moderate and never life-threatening. In no case was impairment of the renal function observed, and the clearance of high-dose Methotrexate was never delayed.
Gasparini
M
M
Tondini
C
C
Rottoli
L
L
Roncoroni
I
I
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D012516:Osteosarcoma / Q000188:drug therapy*; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D014750:Vincristine; D002945:Cisplatin; D008727:Methotrexate